1. Home
  2. TNXP vs EHI Comparison

TNXP vs EHI Comparison

Compare TNXP & EHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$11.09

Market Cap

198.6M

Sector

Health Care

ML Signal

HOLD

EHI

Western Asset Global High Income Fund Inc

HOLD

Current Price

$5.90

Market Cap

181.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
EHI
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
198.6M
181.8M
IPO Year
2008
2003

Fundamental Metrics

Financial Performance
Metric
TNXP
EHI
Price
$11.09
$5.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
430.5K
92.5K
Earning Date
05-11-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.21
$5.80
52 Week High
$69.65
$6.70

Technical Indicators

Market Signals
Indicator
TNXP
EHI
Relative Strength Index (RSI) 37.57 35.05
Support Level N/A $5.89
Resistance Level $14.85 $6.46
Average True Range (ATR) 0.91 0.07
MACD -0.24 -0.00
Stochastic Oscillator 3.39 9.38

Price Performance

Historical Comparison
TNXP
EHI

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About EHI Western Asset Global High Income Fund Inc

Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income and total return by investing in a world-wide portfolio of securities. The fund invests in various sectors such as Consumer Discretionary, Financials, Energy, Communication energy, Industrials, materials, and others.

Share on Social Networks: